Kiox moves closer to clinic
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease. The new agreement entails revenues of SEK 2.7 million for Iconovo during 2024. The project is based on a reformulation of an FDA approved drug substance in one of Iconovo's patented inhalers; ICOcap. The aim is to develop a new inhalable treatment for interstitial lung diseases (ILD). The value of the ILD treatment market was over USD 4 billion in 2022. https://lnkd.in/dwQbKKWc